Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1979 1
1980 4
1981 8
1982 9
1983 6
1984 9
1985 18
1986 13
1987 22
1988 23
1989 38
1990 42
1991 18
1992 32
1993 43
1994 46
1995 56
1996 62
1997 65
1998 68
1999 90
2000 100
2001 122
2002 128
2003 195
2004 207
2005 258
2006 295
2007 332
2008 433
2009 472
2010 499
2011 621
2012 683
2013 767
2014 902
2015 1038
2016 1071
2017 1183
2018 1280
2019 1490
2020 1717
2021 2025
2022 2477
2023 2361
2024 2416
2025 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,233 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: jin y. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Amyloid-β-targeting immunotherapies for Alzheimer's disease.
Jin Y, Du Q, Song M, Kang R, Zhou J, Zhang H, Ding Y. Jin Y, et al. J Control Release. 2024 Nov;375:346-365. doi: 10.1016/j.jconrel.2024.09.012. Epub 2024 Sep 18. J Control Release. 2024. PMID: 39271059 Review.
Pharmacological effects of berberine on mood disorders.
Fan J, Zhang K, Jin Y, Li B, Gao S, Zhu J, Cui R. Fan J, et al. Among authors: jin y. J Cell Mol Med. 2019 Jan;23(1):21-28. doi: 10.1111/jcmm.13930. Epub 2018 Nov 18. J Cell Mol Med. 2019. PMID: 30450823 Free PMC article. Review.
The Role of KLF4 in Alzheimer's Disease.
Cheng Z, Zou X, Jin Y, Gao S, Lv J, Li B, Cui R. Cheng Z, et al. Among authors: jin y. Front Cell Neurosci. 2018 Sep 21;12:325. doi: 10.3389/fncel.2018.00325. eCollection 2018. Front Cell Neurosci. 2018. PMID: 30297986 Free PMC article. Review.
21,233 results
You have reached the last available page of results. Please see the User Guide for more information.